NYU Lung Cancer Biomarker Center
- Identify and validate biomarkers for the early detection of lung cancer in individuals
at low- or high-risk for smoking-related cancers.
- Identify preneoplastic cellular changes and lesions in these patients.
OUTLINE: Participants are stratified according to lung cancer risk status (with or without
Group 1 (screening cohort): Participants complete a questionnaire and undergo pulmonary
function testing, multidetector chest CT scan, sputum induction, and phlebotomy.
Group 2 (rule-out lung cancer): Participants complete the same questionnaire and undergo the
same tests and scans as in group 1. Some participants may undergo fiberoptic bronchoscopy
based upon CT scan results with transbronchial or endobronchial biopsies. Some participants
may undergo lung resection. Tissue samples are collected from surgery or biopsy.
PROJECTED ACCRUAL: A total of participants will be accrued for this study.
Observational Model: Cohort, Time Perspective: Prospective
Lung cancer diagnosis as measured by CT scan findings and pathology findings annually
William N. Rom, MD, MPH
New York University School of Medicine
United States: Institutional Review Board
|NYU Cancer Institute at New York University Medical Center||New York, New York 10016|